Comparing two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer

Radiation Oncology

Volumn 3, Issue 1, 2008, Pages

  Yuen, Jasper ^a   Rodrigues, George ^a,b   Trenka, Kristina ^a   Coad, Terry ^a   Yartsev, Slav ^a   D'Souza, David ^a   Lock, Michael ^a   Bauman, Glenn ^a  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; METHODOLOGY; PROSTATE TUMOR; RADIATION DOSE; RADIATION RESPONSE;

DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 39749200793     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-3-1     Document Type: Article

References (45)

1. Canadian Cancer Society/National Cancer Institute of Canada Canadian Cancer Statistics 2006 Toronto, Canada 2006
2. Lukka H Warde P Pickles T Morton G Brundage M Souhami L Canadian GU Radiation Oncologist Group Controversies in prostate cancer radiotherapy: Consensus development Can J Urol 2001, 8:1314-1322. 11564274
3. Roach M 3rd DeSilvio M Lawton C Uhl V Machtay M Seider MJ Rotman M Jones C Asbell SO Valicenti RK Han S Thomas CR Jr Shipley WS Radiation Therapy Oncology Group 9413 Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation therapy oncology group 9413 J Clin Oncol 2003, 21:1904-1911. 10.1200/JCO.2003.05.004 12743142
4. Bolla M Collette L Blank L Warde P Dubois JB Mirimanoff RO Storme G Bernier J Kuten A Sternberg C Mattelaer J Lopez Torecilla J Pfeffer JR Lino Cutajar C Zurlo A Pierart M Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 2002, 360:103-106. 10.1016/S0140-6736(02)09408-4 12126818
5. Hanks GE Pajak TF Porter A Grignon D Brereton H Venkatesan V Horwitz EM Lawton C Rosenthal SA Sandler HM Shipley WU Radiation Therapy Oncology Group Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The radiation therapy oncology group protocol 92-02 J Clin Oncol 2003, 21:3972-3978. 10.1200/JCO.2003.11.023 14581419
6. Pollack A Zagars GK Starkschall G Antolak JA Lee JJ Huang E von Eschenbach AC Kuban DA Rosen I Prostate cancer radiation dose response: Results of the M. D. anderson phase III randomized trial Int J Radiat Oncol Biol Phys 2002, 53:1097-1105. 10.1016/S0360-3016(02)02829-8 12128107
7. Valicenti RK Winter K Cox JD Sandler HM Bosch W Vijayakumar S Michalski J Purdy J RTOG 94-06: Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? Int J Radiat Oncol Biol Phys 2003, 57:614-620. 10.1016/S0360-3016(03)00640-0 14529764
8. Bos LJ Damen EM de Boer RW Mijnheer BJ McShan DL Fraass BA Kessler ML Lebesque JV Reduction of rectal dose by integration of the boost in the large-field treatment plan for prostate irradiation Int J Radiat Oncol Biol Phys 2002, 52:254-265. 10.1016/S0360-3016(01)02676-1 11777644
9. Amer AM Mott J Mackay RI Williams PC Livsey J Logue JP Hendry JH Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 2003, 56:199-207. 10.1016/S0360-3016(03)00086-5 12694839
10. Beckendorf V Guerif S Le Prise E Cosset JM Lefloch O Chauvet B Salem N Chapet O Bourdin S Bachaud JM Maingon P Lagrange JL Malissard L Simon JM Pommier P Hay MH Dubray B Luporsi E Bey P The GETUG 70 gy vs. 80 gy randomized trial for localized prostate cancer: Feasibility and acute toxicity Int J Radiat Oncol Biol Phys 2004, 60:1056-1065. 10.1016/ j.ijrobp.2004.05.033 15519775
11. Pollack A Zagars GK Smith LG Lee JJ von Eschenbach AC Antolak JA Starkschall G Rosen I Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 gy with 78 gy for prostate cancer J Clin Oncol 2000, 18:3904-3911. 11099319
12. Hanks GE Hanlon AL Pinover WH Horwitz EM Schultheiss TE Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy Cancer J Sci Am 1999, 5:152-158. 10367171
13. Hanks GE Hanlon AL Schultheiss TE Pinover WH Movsas B Epstein BE Hunt MA Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions Int J Radiat Oncol Biol Phys 1998, 41:501-510. 10.1016/S0360-3016(98)00089-3 9635695
14. Zelefsky MJ Leibel SA Kutcher GJ Fuks Z Three-dimensional conformal radiotherapy and dose escalation: Where do we stand? Semin Radiat Oncol 1998, 8:107-114. 10.1016/S1053-4296(98)80006-4 9516591
15. Haustermans KM Hofland I Van Poppel H Oyen R Van de Voorde W Begg AC Fowler JF Cell kinetic measurements in prostate cancer Int J Radiat Oncol Biol Phys 1997, 37:1067-1070. 10.1016/S0360-3016(96)00579-2 9169814
16. Wang JZ Guerrero M Li XA How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys 2003, 55:194-203. 10.1016/ S0360-3016(02)03828-2 12504054
17. Wang JZ Li XA Yu CX DiBiase SJ The low alpha/beta ratio for prostate cancer: What does the clinical outcome of HDR brachytherapy tell us? Int J Radiat Oncol Biol Phys 2003, 57:1101-1108. 10.1016/ S0360-3016(03)00747-8 14575842
18. Brenner DJ Hall EJ Fractionation and protraction for radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 1999, 43:1095-1101. 10.1016/S0360-3016(98)00438-6 10192361
19. Fowler J Chappell R Ritter M Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001, 50: 1021-1031. 10.1016/ S0360-3016(01)01607-8 11429230
20. Brenner DJ Martinez AA Edmundson GK Mitchell C Thames HD Armour EP Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue Int J Radiat Oncol Biol Phys 2002 52 6 13. 10.1016/ S0360-3016(01)02664-5 11777617
21. King CR Fowler JF A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low Int J Radiat Oncol Biol Phys 2001, 51:213-214. 10.1016/S0360-3016(01)01651-0 11516871
22. Kal HB Van Gellekom MP How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys 2003, 57:1116-1121. 10.1016/ S0360-3016(03)01455-X 14575844
23. Brenner DJ Toward optimal external-beam fractionation for prostate cancer Int J Radiat Oncol Biol Phys 2000, 48:315-316. 10.1016/ S0360-3016(00)00591-5 10974441
24. Fowler JF Ritter MA Chappell RJ Brenner DJ What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003, 56:1093-1104. 10.1016/S0360-3016(03)00132-9 12829147
25. Brenner DJ Hypofractionation for prostate cancer radiotherapy - what are the issues? Int J Radiat Oncol Biol Phys 2003, 57:912-914. 10.1016/ S0360-3016(03)01456-1 14575821
26. Shih HA Harisinghani M Zietman AL Wolfgang JA Saksena M Weissleder R Mapping of nodal disease in locally advanced prostate cancer: Rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy Int J Radiat Oncol Biol Phys 2005, 63:1262-9. 10.1016/j.ijrobp.2005.07.952 16253781
27. Shepard DM Olivera GH Reckwerdt PJ Mackie TR Iterative approaches to dose optimization in tomotherapy Phys Med Biol 2000, 45:69-90. 10.1088/ 0031-9155/45/1/306 10661584
28. Papanikolaou N Mackie TR Meger-Wells C Gehring M Reckwerdt P Investigation of the convolution method for polyenergetic spectra Med Phys 1993, 20:1327-1336. 10.1118/1.597154 8289713
29. Lu W Olivera GH Chen ML Reckwerdt PJ Mackie TR Accurate convolution/ superposition for multi-resolution dose calculation using cumulative tabulated kernels Phys Med Biol 2005, 50:655-680. 10.1088/0031-9155/50/4/ 007 15773626
30. Grigorov G Kron T Wong E Chen J Sollazzo J Rodrigues G Optimization of helical tomotherapy treatment plans for prostate cancer Phys Med Biol 2003, 48:1933-1943. 10.1088/0031-9155/48/13/306 12884926
31. Nutting CM Convery DJ Cosgrove VP Rowbottom C Padhani AR Webb S Dearnaley DP Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer Int J Radiat Oncol Biol Phys 2000, 48:649-656. 10.1016/S0360-3016(00)00653-2 11020560
32. Lebesque JV Keus RB The simultaneous boost technique: The concept of relative normalized total dose Radiother Oncol 1991, 22:45-55. 10.1016/ 0167-8140(91)90068-R 1947212
33. Schuster-Uitterhoeve AL Hulshof MC Gonzalez Gonzalez D Koolen M Sminia P Feasibility of curative radiotherapy with a concomitant boost technique in 33 patients with non-small cell lung cancer (NSCLC) Radiother Oncol 1993, 28:247-251. 10.1016/0167-8140(93)90065-G 8256003
34. Heukelom S Lanson JH Mijnheer BJ Quality assurance of the simultaneous boost technique for prostatic cancer: Dosimetric aspects Radiother Oncol 1994, 30:74-82. 10.1016/0167-8140(94)90012-4 8153384
35. Butler EB Teh BS Grant WH 3rd Uhl BM Kuppersmith RB Chiu JK Donovan DT Woo SY Smart (simultaneous modulated accelerated radiation therapy) boost: A new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy Int J Radiat Oncol Biol Phys 1999, 45:21-32. 10.1016/S0360-3016(99)00101-7 10477002
36. Wu Q Manning M Schmidt-Ullrich R Mohan R The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: A treatment design study Int J Radiat Oncol Biol Phys 2000, 46:195-205. 10.1016/S0360-3016(99)00304-1 10656393
37. Mohan R Wu Q Manning M Schmidt-Ullrich R Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers Int J Radiat Oncol Biol Phys 2000, 46:619-630. 10.1016/S0360-3016(99)00438-1 10701741
38. Bos LJ Damen EM de Boer RW Mijnheer BJ McShan DL Fraass BA Kessler ML Lebesque JV Reduction of rectal dose by integration of the boost in the large-field treatment plan for prostate irradiation Int J Radiat Oncol Biol Phys 2002, 52:254-265. 10.1016/S0360-3016(01)02676-1 11777644
39. Mott JH Livsey JE Logue JP Development of a simultaneous boost IMRT class solution for a hypofractionated prostate cancer protocol Br J Radiol 2004, 77:377-386. 10.1259/bjr/66104316 15121701
40. Li XA Wang JZ Jursinic PA Lawton CA Wang D Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer Int J Radiat Oncol Biol Phys 2005, 61:1251-1257. 10.1016/j.ijrobp.2004.11.034 15752907
41. Gregoire V Levendag P Ang KK Bernier J Braaksma M Budach V Chao C Coche E Cooper JS Cosnard G Eisbruch A El-Sayed S Emami B Grau C Hamoir M Lee N Maingon P Muller K Reychler H CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines Radiother Oncol 2003, 69:227-236. 10.1016/j.radonc.2003.09.011 14644481
42. Levendag P Braaksma M Coche E van Der Est H Hamoir M Muller K Noever I Nowak P van Sörensen De Koste J Grégoire V Rotterdam and brussels CT-based neck nodal delineation compared with the surgical levels as defined by the american academy of otolaryngology-head and neck surgery Int J Radiat Oncol Biol Phys 2004, 58:113-123. 10.1016/ S0360-3016(03)01453-6 14697428
43. Harisinghani MG Barentsz J Hahn PF Deserno WM Tabatabaei S van de Kaa CH dela Rosette J Weissleder R Noninvasive detection of clinically occult lymph-node metastases in prostate cancer N Engl J Med 2003, 348:2491-9. 10.1056/NEJMoa022749 12815134
44. Taupitz M Hamm BK Barentsz JO Vock P Roy C Bellin MF Sinerem-enhanced MRI imaging compared to plain MR imaging in evaluating lymph node metastases from urologic and gynaecologic cancers [abstract] Proceedings of the Radiological Society of North America, Chicago, IL 1999 s387
45. Anzai Y Piccoli CW Outwater EK Stanford W Bluemke DA Nurenberg P Saini S Maravilla KR Feldman DE Schmiedl UP Brunberg JA Francis IR Harms SE Som PM Tempany CM Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: Phase III safety and efficacy study Radiology 2003, 228:777-88. 10.1148/radiol.2283020872 12954896